Skip to content

MB NEUROLOGIE

Active
Private limited companyfounded 2024active for 2 yearsBosstraat 547, 1150 Sint-Pieters-Woluwe, BelgiumKBO/BCE: BE 1014.720.859
Summary

MB NEUROLOGIE has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €110,998 and a net result of €109,998. The computed 12-month bankruptcy probability is 0.6% (low).

Overview

Activity
Activity not known1 site
Size
€143,718total assets 2025
Equity
€110,998
Profit
€109,998
Turnover not published (micro format)
Financial health
73 Healthy Checked score 2025
Bankruptcy probabilitywithin 12 months
0.6%
Structure
2025 accounts 25 days early
Why 73raises risk1 change of registered office in 24 monthslowers riskLiquidity: current ratio 4.39, cash €72,980Size: total assets €143,718Figures for financial year 2025 (filed 06-07-2026)Show the evidence

Checked score

Score 2025
73 / 100
Healthy
Probability in this band: 0.55% to 1.5%
Financially better than 85% of its sector peers (no NACE code, micro)
Financial strength
Strong
Solvency 100
equity 77.2% of total assets
Liquidity 92
short-term debt 22.8% · cash 50.8%
Profitability 100
return on assets 76.5%
Bankruptcy probability, 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%

About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 11-2025: 2.5% 12-2025: 2.6%▲ +0.1 percentage points vs 11-2025 01-2026: 2.6%● unchanged vs 12-2025 02-2026: 3.2%▲ +0.6 percentage points vs 01-2026 03-2026: 3.2%● unchanged vs 02-2026 04-2026: 3.5%▲ +0.3 percentage points vs 03-2026 05-2026: 3.7%▲ +0.2 percentage points vs 04-2026highest value 06-2026: 3.7%● unchanged vs 05-2026 07-2026: 3.6%▼ -0.1 percentage points vs 06-2026 08-2026: 0.2%▼ -3.4 percentage points vs 07-2026lowest value 09-2026: 0.6%▲ +0.4 percentage points vs 08-2026 10-2026: 0.6%● unchanged vs 09-2026
Credit of up to €8,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity ample (current ratio 4.39, above the usual 1.5; short-term debt: 22.8% and cash: 50.8% of total assets), and 22.8% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro): better than 81% on solvency, 83% on liquidity and 90% on profitability.

The bankruptcy probability was computed on 26-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
lowers risk · Liquidity: current ratio 4.39, cash €72,980
NBB · annual accounts
lowers risk · Size: total assets €143,718
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
lowers risk · Figures for financial year 2025 (filed 06-07-2026)
NBB · annual accounts
raises risk · Young company
Founded in 2024, 2 years ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 years
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 06-07-2026, 25 days ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2025
25 days early
← before the deadline after the deadline →
Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2024.
KBO publications · our coverage
  1. Registered officeRegistered-office move
  2. Annual accounts filedfinancial year 2025 · micro…
  3. IncorporationAppointment: BRONCHAIN Maroussia Annick Bruno…

Key points

  • One director decidessole director in office 1 View
  • Total assets 2025first financial year filed €143,718 View
  • Active since 2024founded 07-10-2024 2 years View

By topic

Financials

Financial year
2025
Total assets
€143,718
Profit
€109,998
Solvency
77.2%
Go to Financials

Company details

Sites
1
Legal form
Private limited company
Founded
07-10-2024
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Key facts about MB NEUROLOGIE

What is the company number of MB NEUROLOGIE?
1014.720.859. In Belgium the VAT number is the company number with BE in front: BE 1014.720.859.
Where is MB NEUROLOGIE based?
The registered office is at Bosstraat 547, 1150 Sint-Pieters-Woluwe.Company details
What is the legal form of MB NEUROLOGIE?
Private limited company (BV).
When was MB NEUROLOGIE founded?
On 07-10-2024.
Is MB NEUROLOGIE still active?
Yes, MB NEUROLOGIE is an active enterprise in the KBO register.
What is the turnover of MB NEUROLOGIE?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is MB NEUROLOGIE profitable?
In financial year 2025, MB NEUROLOGIE made a profit of €109,998.
Where can I find the annual accounts of MB NEUROLOGIE?
MB NEUROLOGIE filed 1 annual account with the National Bank of Belgium, for financial year 2025.

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.